Background: Transcatheter aortic valve implantation (TAVI) has evolved as an effective treatment in patients with symptomatic severe aortic stenosis (AS) and increased operative risk. Data on the influence of previous sternotomy on the risk of TAVI are limited.
Impact of previous cardiac surgery with sternotomy on clinical outcomes and quality of life after transcatheter aortic valve implantation for severe aortic stenosis 
INTRODUCTION
Transcatheter aortic valve implantation (TAVI) has been demon strated as an effective treatment in patients with symptomatic severe aortic stenosis (AS) and increased operative risk [1] [2] [3] . An improvement in clinical outcomes and quality of life (QoL) after TAVI in long-term follow-up was confirmed by several studies [4] [5] [6] [7] [8] . Patients with previous cardiac surgery are con sidered to be at increased perioperative risk for redo cardiac operations [9, 10] . Previous cardiac surgery imposes additional risks on patients undergoing median sternotomy [11] [12] [13] . Furthermore, patients with a history of coronary artery bypass grafting (CABG) may face an additional risk of damage to the graft, which is associated with worse periprocedural outcomes [11] [12] [13] . Nowadays, these patients constitute a considerable portion of those with severe AS referred for TAVI due to the minimally invasive nature of this approach. However, out comes of patients with previous sternotomy undergoing TAVI are still under investigation. Thus, we sought to investigate the impact of previous cardiac surgery with sternotomy on clinical outcomes and QoL after TAVI.
METHODS
A complete description was reported previously [14] . We en rolled 148 consecutive patients who underwent TAVI. All the patients had symptomatic severe AS and high periprocedural risk or contraindications for surgical aortic valve replacement. The eligibility for TAVI was based on the consensus of the multidisciplinary Heart Team. Baseline characteristics and proce dural data were collected prospectively. TAVI procedures were performed using Edwards Sapien, Edwards Sapien XT, Edwards Sapien 3 (Edwards Lifesciences, Irvine, CA, USA), Medtronic CoreValve/Evolut R (Medtronic, Inc., Minneapolis, MN, USA), JenaValve (JenaValve Technology, Munich, Germany), Lotus (Boston Scientific), and New Valve Technology transcatheter heart valves. The decision about the type and size of the valve as well as the access route was at the discretion of the Heart Team and treating physicians. Procedures were performed under general anaesthesia or local anaesthesia with sedation. Clinical endpoints of the study included all-cause mortality at 30 days and every six months up to maximal available fol low-up and complications rate up to 12 months. QoL was as sessed with the validated Polish version of the EQ-5D-3L ques tionnaire at baseline and 12 months after TAVI. The visual ana logue scale (VAS) score, which is a part of the EQ-5D-3L, was also assessed. Outcome endpoints were in accordance with Valve Academic Research Consortium definitions (VARC-2) [15] . For this analysis, patients were divided into two groups according to the presence of cardiac surgery with sternotomy. Written informed consent was collected from each patient included in the study. The study was approved by the insti tutional ethical board and was conducted according to the ethical guidelines of the 1975 Declaration of Helsinki with later amendments.
Statistical analysis
Results are presented as number of patients (percentage) or median (interquartile range [IQR] ), where applicable. Differ ences between groups were tested using the c 2 test and Fisher's exact test for dichotomous variables and the Mann-Whitney U-test for continuous variables. Changes in EQ-5D-3L ques tionnaire between baseline and follow-up evaluations were analysed using McNemar's test. The relationship between baseline and follow-up responses in the VAS score were analysed with a Wilcoxon signed-rank test. Comparisons of baseline and 12-month outcomes were calculated excluding unpaired results. The difference in mortality between patients with and without previous sternotomy during follow-up was assessed with Kaplan-Meier method. In addition, differences in outcomes were presented as odds ratios (ORs) adjusted for age/sex/previous myocardial infarction (MI) with 95% confidence intervals (CIs). Multivariable Cox regression model was constructed to identify significant predictors of 12-month mortality. All baseline characteristics and procedural data were considered and forward selection with a probability value for covariates to enter the model of 0.05 was used. Results were presented as hazard ratios (HRs) with 95% CI. All tests were two-tailed, and a p-value of < 0.05 was considered statisti cally significant. All statistical analyses were performed using SPSS 15.0 (SPSS, Inc., Chicago, IL, USA).
RESULTS
Of the 148 consecutive patients undergoing TAVI, previ ous cardiac surgery with sternotomy was confirmed in 34 (23.0%), and previous CABG was the reason for ster notomy in 28 (82.4%) of these 34 patients with a history of cardiac surgery. Patients with previous sternotomy were younger and were more often male, with a higher rate of previous MI (26 [ Table 2 . A comparable length of hospital stay was ob served in patients with and without a history of sternotomy (Table 3) . Median follow-up of all patients was 13.3 (6.0-31.1) months. There were no differences in 30-day and 12-month all-cause mortality between groups (sternotomy [-] 
DISCUSSION
The results of this study suggest no impact of previous car diac surgery with sternotomy on the risk of adverse events in patients undergoing TAVI as compared with patients with no Figure 1 . Proportions of patients reporting either "some problems" or "extreme problems" for each category of the EQ-5D-3L at baseline and 12 months history of chest opening. These results were maintained after the adjustment for age, sex, and previous MI. No differences in the results of QoL assessment were observed between groups. Previous sternotomy was not identified as an independent predictor of all-cause long-term mortality. Observed higher long-term mortality in patients without previous sternotomy might be partially related to some differences in age and baseline risk profile between groups. These data stay in line with results from most recent studies reporting no influence of prior cardiac surgery on survival rate after TAVI. A recent large meta-analysis has reported no significant difference in 30-day and one-year all-cause mortality between patients undergoing TAVI with and without a history of previous cardiac surgery with sternotomy (risk ratio 0.95, 95% CI 0.82-1.09, p = 0.55; risk ratio 0.94, 95% CI 0.86-1.02, p = 0.48, respectively) [16] . In addition, results of subgroup analysis including only patients with a history of CABG also did not show differences between those groups [16] . Interestingly, the rate of major vascular complications was marginally lower in patients with previous cardiac surgery, but the calculation was not robust because the result lost significance in sensitivity analysis [16] . Also, the risk of acute MI was significantly higher in patients with prior sternotomy, but a higher prevalence of coronary artery disease (CAD) and diabetes mellitus in the previous cardiac surgery group was the probable reason for this worse outcome [16] . However, most of the included studies were non-randomised or were post hoc analyses of randomised trials; thus, it may have limited the external validity of the analysis. In our study, no difference in the rate of all complications was confirmed. Several studies reported comparable clinical outcomes be tween patients with and without a history of prior cardiac surgery with sternotomy [17] [18] [19] [20] [21] . However, Ducrocq et al. [22] reported better survival in patients with previous CABG undergoing TAVI. Multivariate analysis identified a history of CABG as an independent predictor of better two-year survival [22] . Conversely, this study also confirmed that transapical ap proach (TA) is a predictor of two-year mortality [22] . On the other hand, these results may be related to the residual bias in an observational nature of this analysis. In our study, we did not take into account variables such as the type of valve and type of vascular approach, which could affect clinical outcomes. Some would argue that TA may be challenging in patients with previous sternotomy undergoing TAVI. Few stud ies have assessed the outcomes of TA use in TAVI patients with prior cardiac operations. The results were similar in patients with and without a history of chest opening [17, [23] [24] [25] [26] . These data suggested that both TA and transfemoral (TF) TAVI are reasonable options in patients with severe AS and previous cardiac operation. In patients with a history of previous car diac surgery with sternotomy, the potential superiority of TAVI is linked to the minimally invasive nature of the procedure [17] . Small mediastinal dissection (in TA-TAVI and transaortic approach) or no incision at all (TF-TAVI and trans-subclavian approach) reduce potential risk related to all complications associated with chest reopening [17] . Furthermore, no need for extracorporeal circulation provides an additional advan tage [17] . In contrast, TAVI does not eliminate the fact that patients with previous CABG have a history of significant CAD, which by itself may result in additive risk [17] . In our study, despite a higher rate of previous MI in patients with a history of sternotomy, the adverse outcomes were not different in comparison with patients with no prior cardiac surgery. The vast majority of redo patients had previous CABG operations (82.4%), but the incidence of perioperative and long-term MI was low. This could be explained by the potential protective function of the patent grafts. Furthermore, all patients under went diagnostic angiography before they were scheduled for TAVI to exclude progression of CAD. Despite mortality being used to measure the effective ness of treatments, QoL should be an additional target [3] [4] [5] . Thus, QoL improvement is commonly considered as a major expectation for elderly patients' profile after TAVI [3-5, 27, 28] . Amelioration of QoL after TAVI may be more beneficial than observed after surgical treatment of severe AS, even in cluding less invasive mini-thoracotomy and mini-sternotomy techniques [8] . In our study, no differences between groups in all components of the EQ-5D-3L questionnaire were confirmed. Similar results in VAS change during follow-up were observed in patients with and without history of cardiac surgery with chest opening. However, numerically higher improvement in patients without previous sternotomy might suggest that this result could reach statistical significance with a higher number of included patients.
Most of the limitations are directly related to the non-ran domised, observational study design. The decision for suitabil ity and eligibility for TAVI was conducted by a multidisciplinary local Heart Team according to current guidelines, although potential bias in patients and treatment selection could af fect the outcomes. Thus, these results should be considered as hypothesis-generating rather than causative. There are also limitations related to the instrument for QoL evaluation. EQ-5D-3L is a generic questionnaire with a low sensitivity. Furthermore, no disease-specific QoL tool was used due to time-consuming evaluation. CABG was the reason for previ ous cardiac surgery in most of the patients. In the remaining six patients (17.6% of this group) the indication for previous cardiac surgery with sternotomy was not documented. Fur thermore, the interval between previous chest opening and TAVI was unknown.
In conclusion, TAVI seems to be a safe and effective technique for the treatment of severe AS in patients with previous cardiac surgery with sternotomy. Similar complica tion rates and QoL outcomes were observed regardless of the status of previous cardiac operations. This observation might lead the Heart Team to consider TAVI as an attractive option in the population of high-risk patients with AS and previous sternotomy.
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